Home Finance Ablexis and AlivaMab Discovery Services Announce Agreements with Almirall to Accelerate Antibody Drug Discovery and Development – Yahoo Finance

Ablexis and AlivaMab Discovery Services Announce Agreements with Almirall to Accelerate Antibody Drug Discovery and Development – Yahoo Finance

0
Ablexis and AlivaMab Discovery Services Announce Agreements with Almirall to Accelerate Antibody Drug Discovery and Development – Yahoo Finance

Ablexis’ multi-target licensing agreement grants Almirall rights to use the AlivaMab® Mouse technology for research, development and commercialization of antibodies. AlivaMab Discovery Services will apply its platforms and team's expertise in antibody drug discovery and engineering to perform the antibody drug discovery for Almirall.
SAN DIEGO, Calif. & BARCELONA, Spain, January 31, 2022–(BUSINESS WIRE)–Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, and AlivaMab Discovery Services, LLC ("ADS"), a leader in the discovery of superior antibody-based therapeutics, today announced a multi-target licensing agreement between Ablexis and Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, and a research partnership between ADS and Almirall.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220131005182/en/
Under the terms of the license with Ablexis, Almirall is granted non-exclusive rights to use the AlivaMab Mouse technology, a state-of-art platform for the generation of human therapeutic antibodies, for the discovery, development and commercialization of antibody drugs.
Almirall selected ADS to conduct the drug discovery research, leveraging ADS’ expertise in antibody drug discovery, antibody engineering and platform processes to deliver drug-quality, fully human antibodies on exceptional timelines, including engineering for alternative modalities.
"These agreements are in line with Almirall’s vision to develop innovative treatment options for patients suffering from severe skin diseases. AlivaMab Discovery Services’ profound know-how in antibody discovery and engineering together with Almirall's expertise in dermatology will strongly accelerate the development of differentiated treatments to help patients get closer to their goal of leading a healthy life," stated Dr. Thomas Huber, Research Director at Almirall. "The agreements highlight the company's commitment to early biologics discovery to provide the best solutions to skin conditions through novel science."
"We are pleased that Almirall has selected the AlivaMab Mouse technology as a key platform for its antibody drug discovery," said Larry Green, Chief Executive Officer at Ablexis, LLC. "Together with the talented and highly experienced team of antibody drug hunters at Ablexis' sister company, AlivaMab Discovery Services, we are increasingly recognized by partners with real experience in antibody drug discovery and development."
"Almirall joins our rapidly expanding list of high-quality partners that leverage the discovery, engineering and developability assessment capabilities of ADS, especially for challenging targets, functional design goals and advanced modalities," said Justin Mika, Chief Executive Officer at AlivaMab Discovery Services. "Our partners appreciate how our team’s expertise, combined with the proven AlivaMab Mouse platform, significantly improves the probability of success and shortens timelines in discovery and development. We look forward to supporting Almirall’s efforts to help patients with dermatological conditions."
About Ablexis, LLC
Ablexis, LLC created and non-exclusively licenses AlivaMab Mouse, a suite of unique, patented next generation transgenic mice, as a platform for human therapeutic antibody discovery. Ablexis has license agreements with dozens of companies, including global pharmaceutical companies, public and private biotechnology companies and other entities. Ablexis continues making AlivaMab Mouse available via non-exclusive licenses. For more information, visit www.ablexis.com. For inquiries, please email info@ablexis.com.
About AlivaMab Discovery Services
AlivaMab Discovery Services (ADS) sets its partners’ antibody discovery programs on the fastest and most de-risked path through discovery and development. Trusted by top-tier pharmaceutical and biotechnology companies, ADS delivers drug-quality, fully human antibodies on exceptional timelines. ADS achieves its partners’ design goals, from simple to extraordinarily challenging, through the generation and function-first screening of large, molecularly diverse panels of antibodies. ADS focuses on rapid and efficient delivery of antibodies, characterized for function, kinetics and developability, and engineering for advanced modalities, including multispecifics and CARs. The ADS team’s experience in antibody drug discovery and development comes from many of the world’s top 15 pharmaceutical companies, including AbbVie, AstraZeneca, Bristol Myers Squibb, Novartis, Pfizer and Roche/Genentech, and translates across more than 500 discovery programs and 35 clinical candidates. This experience, combined with the use of trusted, proven technologies, including Ablexis’ AlivaMab® Mouse platforms, ensures the highest probability of success. For more information, please visit www.alivamab.com or email info@alivamab.com.
About Almirall
Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.
The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 78-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2020 were 814.5 million euros.
For more information, please visit www.almirall.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220131005182/en/
Contacts
AlivaMab Discovery Services Contacts
BD Contact:
info@alivamab.com
Media Contact:
Stacey Borders
sborders@alivamab.com
(858) 252-3420 x105
Almirall Contacts
Media Contact:
Tinkle
Laura Blázquez
lblazquez@tinkle.es
(+34) 600 430 581
Investors’ Relations Contact:
Almirall
Pablo Divasson del Fraile
pablo.divasson@almirall.com
(+34) 93 291 3087
Corporate Communications Contact:
Almirall
Maria Duro
maria.duro@almirall.com
(+34) 671 580 492
With the tech-heavy Nasdaq stock index up 2.5% as of 1:20 p.m. ET, it looks like investors have decided that Monday will be a "risk-on" day for the stock market. It's no great surprise, then, that some of the riskiest stocks around — space stocks — are flying higher. Astra Space (NASDAQ: ASTR) was up 9.3%.
Spotify's weekend in the headlines continued as more artists and podcasters objected to its stance.
Changing salinity levels and impacts to plant and animal species are some concerns scientists have after the A-68a “megaberg” nearly crashed into South Georgia Island.
SpaceX will try ‘one more time’ to launch the rocket after its fourth attempt fails
Before humans can settle off-Earth, scientists need to figure out how — or even whether — people can reproduce in space.Why it matters: Powerful figures in the space industry like Elon Musk and Jeff Bezos have dreams of a future where millions of people live in space, which would naturally require a self-sustaining population of humans somewhere other than Earth. Stay on top of the latest market trends and economic insights with Axios Markets. Subscribe for free"It has been [more than] 20 years
OVR Technology, a Burlington company that brought the sense of smell to virtual reality, has been recognized with an international award.
Deepnote, a startup that is building a data science platform on top of Jupyter-compatible notebooks, today announced that it has raised a $20 million Series A round co-led by Index Ventures and Accel, both of which participated in its 2020 seed round. Existing investors Y Combinator and Credo Ventures also participated in this round. As Deepnote co-founder and CEO Jakub Jurovych told me, the company has pretty much stayed true to its original vision since its launch a couple of years ago.
Last year, Ember outlined one of the more fascinating expansions of recent vintage we’ve seen in the hardware space. What began as a conversation was bolstered by a $23.5 million raise last year, and now the firm has a new product — and partnership to showcase where things go from here. The centerpiece of the new direction is the Ember Cube — what the company calls “the world’s first self-refrigerated, cloud-based shipping box.”
SpaceX delayed the launch of a Falcon 9 rocket from Cape Canaveral Space Force Station a third time Saturday, citing poor weather for the push.
Elon Musk reached out to a 19-year-old last fall over Twitter DM to ask him to stop tracking his flights
Scientists have created a 3D map of an ultra-hot exoplanet that could help discover habitable worlds.
The Institut national de la recherche scientifique (INRS) has launched a major project in collaboration with Quebec Silica Resources. This research partnership will optimize exploration and mining methods while respecting the environment and the local biodiversity.
Don't miss a prime chance to spot Orion in the night sky.
Experts are also calling BA.2 a "stealth omicron," as there's a key difference in its genetic sequence that makes it harder to track.
A cruise ship veered into the exclusion zone along a Falcon 9 rocket's flightpath Sunday evening, forcing SpaceX to scrub the mission yet again.
Orcas — aka killer whales — have been documented killing and blue whales, which may actually be a positive sign.
Carbon reduction and lab requirements can be opposing forces. But pioneering efforts are revealing a roadmap to a healthier environment and better science.
(Bloomberg) — Sign up for the New Economy Daily newsletter, follow us @economics and subscribe to our podcast.Most Read from BloombergCovid-Infected HIV Patient Developed Mutations, Study ShowsAn Army of Faceless Suits Is Taking Over the $4 Trillion Hedge Fund WorldFutures Signal U.S. May Trail Global Equity Rally: Markets WrapSpotify Adds Covid Notices in Effort to Stop Rogan BoycottsBoeing Is Set to Launch Its First New Jet in Nearly Five Years With 50-Plane Qatar DealAustralia’s central bank
British businesses are scaling back plans for pay rises and hiring, but almost half intend to increase the prices they charge customers as they seek to manage rapidly rising costs, a survey showed on Monday. The figures from a monthly Lloyds Bank survey will give mixed signals to the Bank of England on the persistence of inflation pressures – and the extent to which they will hamper growth – as it considers a widely expected rate rise this week. A record 49% of the 1,200 businesses surveyed between Jan. 4 and Jan. 18 said they expected to raise prices, up from 45% in December.
Google parent company Alphabet will report its Q4 earnings after the bell on Tuesday.

source

LEAVE A REPLY

Please enter your comment!
Please enter your name here